Company / Shareholders' Equity
CG Oncology, Inc. Shareholders' Equity History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$752.6M
FY2025
5-year range
-$123.1M / $752.6M
FY2023-FY2025
Trend
+2.6%
vs FY2024
Sector context
#58 of 213
Health Care
What the data says
At $753M, CG Oncology, Inc.'s shareholders' equity ranks #58 of 213 in the Health Care sector. Improved from -$123M to $753M over the past 2 years.
Based on SEC 10-K filings.
$753M in FY2025.
Improved from -$123M to $753M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#58 of 213 in Health CareTop 27% of 213This company $752.6M Sector average $2.5B
▼
-70.5% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 2.6% year-over-year.
- Ranks #58 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 8.02 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $752.6M | +2.6% |
| FY2024 | $733.4M | +695.8% |
| FY2023 | -$123.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026